for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Intersect ENT Inc

XENT.OQ

Latest Trade

18.60USD

Change

0.41(+2.25%)

Volume

153,406

Today's Range

18.02

 - 

18.69

52 Week Range

15.13

 - 

35.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.19
Open
18.13
Volume
153,406
3M AVG Volume
8.63
Today's High
18.69
Today's Low
18.02
52 Week High
35.84
52 Week Low
15.13
Shares Out (MIL)
31.47
Market Cap (MIL)
569.97
Forward P/E
-12.55
Dividend (Yield %)
--

Next Event

Q3 2019 Intersect Ent Inc Earnings Release

Latest Developments

More

Intersect Ent Posts Q2 Loss Per Share Of $0.36

Intersect Ent Announces FDA Approval Of New Propel Mini Straight Delivery System

Intersect Ent Announces Appointment Of Thomas West As CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Intersect ENT Inc

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry

Medical Equipment & Supplies

Contact Info

1555 Adams Dr

+1.650.6412100

http://www.intersectent.com/

Executive Leadership

Kieran T. Gallahue

Executive Chairman of the Board

Thomas A. West

President, Chief Executive Officer, Director

Jeryl L. Hilleman

Chief Financial Officer

Christine R. Kowalski

Chief Operating Officer

David A. Lehman

General Counsel

Key Stats

2.30 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.890

2017

-0.560

2018

-0.760

2019(E)

-1.443
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.15
Price To Book (MRQ)
4.83
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-28.90
Return on Equity (TTM)
-25.82

Latest News

BRIEF-Intersect ENT Reports Qtrly Loss Per Share $0.21

* Q1 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S

BRIEF-Intersect ENT Q4 Revenue $29.5 Million

* INTERSECT ENT REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Intersect ENT Reports Preliminary Q4 And Year 2017 Revenue

* - CO CONTINUES TO EXPECT TO LAUNCH SINUVA COMMERCIALLY IN Q2 OF 2018

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

* James Flynn reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (http://bit.ly/2jwmJXW) Further company coverage:

BRIEF-FDA performs pre-approval inspection of Intersect ENT's menlo park facility

* FDA performs pre-approval inspection of Intersect ENT's menlo park facility

BRIEF-Intersect ENT Inc reports Q3 revenue $22.3 million

* Intersect ENT Inc - outlook for 2017 gross margin continues to be about 84%

BRIEF-Intersect ENT qtrly net loss per share $0.08

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Intersect Ent Q1 revenue $20.5 million

* Q1 earnings per share view $-0.25, revenue view $19.4 million -- Thomson Reuters I/B/E/S

BRIEF-Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease

* Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease

BRIEF-Intersect ENT says FDA approves steroid releasing implant Propel Contour

* Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses

BRIEF-Intersect ENT sees FY 2016 revenue about $78 million

* Intersect ENT Inc - Company is raising its annual outlook for gross margin to approximately 83% versus prior guidance 82%-83%

BRIEF-Intersect ENT announces positive clinical results of pivotal study of RESOLVE In-Office steroid releasing implant

* Intersect ENT announces positive clinical results of pivotal study of resolve in-office steroid releasing implant

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up